Evidence map›Paper›PMID 39910379›Full record

ArticleNature metabolism2025

Subcutaneous depth-selective spectral imaging with mμSORS enables noninvasive glucose monitoring.

Yifei Zhang, Lili Zhang, Long Wang, Shuai Shao, Bei Tao, Chunrui Hu, Yufei Chen, Yue Shen, Xianbiao Zhang, Shijia Pan and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Enzyme-Activated MRI for In Vivo Glucose Imaging via a Biodegradable Chromium Nanoprobe.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yifei Zhang *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0003-0272-0602
Lili Zhang *Shanghai Photonic View Technology Co., Ltd, Shanghai, China.
Long Wang *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0002-2274-177X
Shuai Shao *Shanghai Photonic View Technology Co., Ltd, Shanghai, China.ORCID http://orcid.org/0000-0002-0916-1578
Bei TaoDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chunrui HuShanghai Photonic View Technology Co., Ltd, Shanghai, China.
Yufei ChenDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yue ShenShanghai Photonic View Technology Co., Ltd, Shanghai, China.
Xianbiao ZhangShanghai Photonic View Technology Co., Ltd, Shanghai, China.ORCID http://orcid.org/0009-0009-9586-5261
Shijia PanDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0009-0009-2122-3477
Hua CaoDepartment of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ming SunShanghai Photonic View Technology Co., Ltd, Shanghai, China.
Jia ShiDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chunhong JiangDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Minghui ChenShanghai Institute for Interventional Medical Devices, School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Lin ZhouShanghai Photonic View Technology Co., Ltd, Shanghai, China. lin.zhou@photonicview.com.ORCID http://orcid.org/0000-0002-9541-7778
Guang NingDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. gning@sibs.ac.cn.ORCID http://orcid.org/0000-0002-5754-7635
Chang ChenShanghai Photonic View Technology Co., Ltd, Shanghai, China. changchen@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-9988-930X
Weiqing WangDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wqingw@shsmu.edu.cn.ORCID http://orcid.org/0000-0001-6027-3084

Funding

Shanghai Shen Kang Hospital Development Center SHDC12024109Shanghai Shen Kang Hospital Development Center SHDC22022301
6 · The paper itself

Abstract

Noninvasive blood glucose monitoring offers substantial advantages for patients, but current technologies are often not sufficiently accurate for clinical applications or require personalized calibration. Here we report multiple μ-spatially offset Raman spectroscopy, which captures Raman signals at varying skin depths, and show that it accurately detects blood glucose levels in humans. In 35 individuals with or without type 2 diabetes, we first determine the optimal depth for glucose detection to be at or below the capillary-rich dermal-epidermal junction, where we observe a strong correlation between specific Raman bands and venous plasma glucose concentrations. In a second study, comprising 230 participants, we then improve accuracy of our regression model to reach a mean absolute relative difference of 14.6%, without personalized calibration, whereby 99.4% of calculated glucose values fall into clinically acceptable zones of the consensus error grid (zones A and B). These findings highlight the ability and robustness of multiple μ-spatially offset Raman spectroscopy for noninvasive blood glucose measurement in a clinical setting.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 2Spectrum Analysis, RamanAdultAgedFemaleHumansMaleMiddle AgedSkinBlood Glucose

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.